Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 642-650

  Steward, W P ^a   Von Pawel, J ^a   Gatzemeier, U ^a   Woll, P ^a   Thatcher, N ^a   Koschel, G ^a   Clancy, L ^a   Verweij, J ^a   De Wit, R ^a   Pfeifer, W ^a   Fennelly, J ^a   Von Eiff, M ^a   Frisch, J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; MESNA; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031917065     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.642     Document Type: Article

References (23)

1. Johnson BE, Ihde DC, Bunn PA, et al: Patients with small cell lung cancer treated with or without irradiation: Data on potential cures, chronic toxicities and late relapses after a 5-11 year follow-up. Ann Intern Med 103:430-438, 1985
2. Thatcher N, Lind M, Stout R, et al: Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. Br J Cancer 60:98-101, 1989
3. Prendiville J, Lorigan P, Hicks F, et al: Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid cycle vincristine with thoracic and cranial irradiation. Eur J Cancer 30:2085-2090, 1994
4. Prendiville J, Radford J, Thatcher N, et al: Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. J Clin Oncol 9:1446-1452, 1991
5. Skipper H: Data and analyses having to do with the influence of dose intensity and duration of treatment (single drugs and combinations) on lethal toxicity and the therapeutic response of experimental neoplasms. Birmingham, AL, Southern Research Institute, Booklets, 13:2-13, 1987
6. Frei E, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
7. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327:28-35, 1992
8. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164-170, 1991
9. Trillet Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29:319-324, 1993
10. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659, 1995
11. Bicknell SR, Steward WP, Semple P, et al: Recombinant human granulocyte-macrophage colony stimulating factor significantly reduces the myelosuppression of intensive combination chemotherapy in patients with small cell lung cancer. Lung Cancer 7:427, 1991 (abstr)
12. Cerny T, Blair V, Anderson H, et al: Pre-treatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 39:146-149, 1987
13. Longo DL, Duffey PL, De Vita VT, et al: The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 9:2042-2051, 1991
14. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
15. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
16. Kaplan E L, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Simon R: Restricted randomization designs in clinical trials. Biometrics 35:549-556, 1979
18. World Health Organisation: Handbook for Reporting the Results of Clinical Treatment. WHO offset publication no. 48. Geneva, Switzerland, World Health Organisation, 1979
19. Miles DW, Fogarty O, Ash RM, et al: Received dose-intensity: A randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 12:77-82, 1994
20. Peters WP, Stuart A, Alfronti ML, et al: Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 72:1310-1315, 1988
21. Bunn PA, Crowley J, Bazuka M, et al: The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group (SWOG). Proc Am Soc Clin Oncol 11:292, 1992 (abstr)
22. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598, 1988
23. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992